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Abstract
Genetic determinants of HDL cholesterol (HDL-C) levels in
the general population are poorly understood. We pre-
viously described plasma cholesteryl ester transfer protein
(CETP) deficiency due to an intron 14 G(+l)-to-A muta-
tion(Intl4 A) in several families with very high HDL-C levels
in Japan. Subjects with HDL-C 100 mg/dl (n = 130) were
screened by PCR single strand conformational polymor-
phism analysis of the CETP gene. Two other mutations were
identified by DNA sequencing or primer-mediated restric-
tion map modification of PCR products: a novel intron 14
splice donor site mutation caused by a T insertion at position
+3 from the exonl4/intronl4 boundary (Intl4 T) and a
missense mutation (Asp'2 to Gly) within exon 15 (D442G).
The Intl4 T mutation was only found in one family. How-
ever, the D442G and Intl4 A mutations were highly preva-
lent in subjects with HDL-C . 60 mg/dl, with combined
allele frequencies of 9%, 12%, 21%, and 43% for HDL-
C 60-79, 80-99, 100-119, and . 120 mg/dl, respectively.
Furthermore, prevalences of the D442G and Intl4 A muta-
tions were extremely high in a general sample of Japanese
men (n = 236), with heterozygote frequencies of 7% and
2%, respectively. These two mutations accounted for about
10% of the total variance of HDL-C in this population. The
phenotype in a genetic compound heterozygote (Intl4 T and
Intl4 A) was similar to that of Intl4 A homozygotes (no
detectable CETP and markedly increased HDL-C), indicat-
ing that the Intl4 T produces a null allele. In four D442G
homozygotes, mean HDL-C levels (86±26 mg/dl) were lower
than in Intl4 A homozygotes (158±35 mgldl), reflecting re-
sidual CETP activity in plasma. In 47 D442G heterozygotes,
mean HDL-C levels were 91±23 mg/dl, similar to the level
in D442G homozygotes, and significantly greater than mean
HDL-C levels in Intl4 A heterozygotes (69±15 mg/dl). Thus,
the D442G mutation acts differently to the null mutations
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with weaker effects on HDL in the homozygous state and
stronger effects in the heterozygotes, suggesting dominant
expression of a partially defective allele. CETP deficiency,
reflecting two prevalent mutations (D442G and Intl4 A),
is the first example of a genetic deficiency state which is
sufficiently common to explain a significant fraction of the
variation in HDL-C in the general population. (J. Clin. In-
vest. 1994. 94:1872-1882.) Key words: cholesteryl ester
transfer protein deficiency * high density lipoprotein -
hyper-alphalipoproteinemia * missense mutation . splice do-
nor site mutation
Introduction
Most prospective epidemiologic studies have shown that in-
creased levels of HDL cholesterol (HDL-C') are an indepen-
dent, negative risk factor for the development of coronary heart
disease (CHD) (1). Recent recommendations of the Adult Treat-
ment Panel H place increased emphasis on the importance of
elevated HDL, regarding HDL-C 2 60 mg/dl (1.55 mmol/liter)
as a beneficial factor that negates one positive CHD risk factor
(2). HDL has a unique ability to facilitate cholesterol efflux
from cells, including those within atherosclerotic lesions, and
subsequently to transport excess cholesterol to the liver (3).
There are several well-known environmental factors influencing
HDL-C levels. Alcohol consumption, exercise, and female sex
increase HDL-C levels. On the other hand, smoking, obesity,
male sex, and diets high in polyunsaturated fat decrease HDL-
C levels (4). These environmental factors often influence HDL
levels through the activities of lipases or lipid transfer proteins
(4, 5). Complex segregation analyses suggest no major gene
determining HDL levels (6, 7); but in some recent studies,
genetic factors appear to be determinants of HDL-C or apo A-
I levels in the general population (8-11). However, the putative
genes involved have not been determined (6-11). In some fami-
lies, cholesteryl ester transfer protein (CETP) deficiency or in-
creased apo A-I production rate have been identified as genetic
factors causing increased HDL-C levels (12, 13).
Plasma CETP mediates the transfer and exchange of choles-
teryl ester (CE) and triglyceride (TG) between the plasma lipo-
proteins, and plays an important role in HDL-CE and apo A-I
1. Abbreviations used in this paper: CE, cholesteryl ester; CETP,
cholesteryl ester transfer protein; CHD, coronary heart disease; CV,
coefficient of variation; D442G, Asp-to-Gly substitution at amino acid
442; FHALP, familial hyperalphalipoproteinemia; HDL-C, HDL choles-
terol; Intl4 A, intron 14 G(+ 1)-to-A; Intl4 T, intron 14 T insertion(+ 3);
SSCP, single-strand conformational polymorphism; TG, triglyceride.
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catabolism, and in the determination of HDL size and subclass
distribution (14). In some primary and secondary hyperlipid-
emias (e.g., familial hypercholesterolemia, dysbetalipoproteine-
mia, hypertriglyceridemia, and nephrotic syndrome) and during
postprandial lipemia, accelerated CETP-mediated CE transfer
results in increased CE net mass transfer from HDL to VLDL
or chylomicron, probably contributing to reduced HDL-CE lev-
els and CE enrichment of potentially atherogenic chylomicron
and VLDL remnants (14). Plasma CETP is a hydrophobic gly-
coprotein with 476 amino acids and 4 N-linked glycosylation
sites (15). The human CETP gene consists of 16 exons encom-
passing 25 kbp on chromosome 16q 13, near the lecithin:choles-
terol acyltransferase and haptoglobin loci (16, 17). Plasma
CETP mRNA is highly expressed in the liver as well as periph-
eral tissues such as spleen, adipose, and muscle (18, 19).
Human genetic CETP deficiency was originally identified
as a splicing defect in Japanese subjects with very high HDL
levels (12). The G(+ 1)-to-A transition at the intron 14 splice
donor site results in a null allele: homozygotes with the mutation
have no CETP in plasma and have marked elevation of HDL-
C (12, 20). Furthermore, genetic deficiency of CETP results in
reduced CE contents in VLDL, intermediate density lipoprotein,
and LDL, producing a potentially antiatherogenic lipoprotein
profiles (20, 21). This mutant allele frequency is high in Japa-
nese subjects with HDL-C levels .60 mg/dl (1.55 mmollliter)
(22). In the present study, we report the phenotype and preva-
lence of other CETP gene mutations. One is a missense mutation
in the carboxy terminal of CETP, which is the same nucleotide
change as the mutation found in two cases with very high HDL-
C levels recently reported (23). The other is a novel splice
donor site mutation caused by a single nucleotide insertion.
Our studies reveal that the missense mutation has a distinctive
phenotype and suggest that its prevalence is so high that it
contributes to the upward skewing of the HDL-C distribution
in a sample of the general Japanese population.
Methods
Subjects
To identify CETP gene mutations in Japanese subjects with high HDL
levels (i.e., familial hyperalphalipoproteinemia [FHALP]), PCR single
strand conformational polymorphism (SSCP) analysis was performed
in 130 consecutive unrelated individuals with increased serum HDL-C
levels (:100 mg/dl) from several regions of Japan. We also screened
for the known intron 14 G(+1)-to-A mutation (Intl4 A) (12, 20, 22).
After the identification of mutations, screening studies were performed
by PCR-based methods both in 130 unrelated subjects with HDL-C
.100 mg/dl and 182 unrelated subjects with HDL-C 60-99 mg/dl
attending the lipid clinic in Kanazawa University Hospital or the affili-
ated clinics in the Kanazawa district. After identification of probands,
medical history, clinical data, and blood samples of family members
were also obtained when possible. To determine the frequencies for
CETP gene mutants in the general Japanese population, we analyzed
the genotypes of 236 healthy Japanese men (age 47±9 yr, mean±SD;
range, 25-69 yr of age) attending the medical clinic of Hokuriku-
Electric Power Co. in Kanazawa for their annual health examinations.
Information on age, cigarette smoking, alcohol consumption, and body
mass index were obtained through questionnaire and interview. 1 U of
alcohol consumption was defined as 633 ml of beer, 180 ml of wine,
180 ml of sake, or 70 ml of hard liquor (- 20-25 g ethanol). Lipid
profiles, plasma CETP activity, and mass determinations were performed
when subjects were not taking any lipid-lowering drugs. No medications
were given unless otherwise noted in the text. Informed consent for all
studies was obtained.
Four pedigrees with CETP deficiency are shown in Fig. 1. Kindred
FHALP-464 contained individuals with both the Intl4 A and intron 14
T insertion (+3) (Intl4 T) mutations as well as a compound heterozy-
gote. This family was from Hiroshima, and all members were healthy.
Kindred FHALP-528 had a compound heterozygote with both the Asp-
to-Gly substitution at amino acid 442 (D442G) and Intl4 A mutations.
This family was from the rural area around Kanazawa. Family members
were all healthy. In kindred FHALP-277, a male proband with mildly
increased HDL levels was found to be heterozygous for the D442G
mutation. He was found to have pulmonary sarcoidosis and vasospastic
angina with a normal coronary angiogram. The diagnosis of vasospasm
was established by an elevation of ST segments in leads II Ill and a VF
induced by intracoronary ergonovine provocation test. He was treated
with diltiazem HCl. He had small bilateral xanthelasma. His lipid pro-
files were serum cholesterol 230±15 mg/dl (n = 6, coefficient of varia-
tion [CV] 6%, and range 208-246 mg/dl), LDL-C 134±10 mg/dl (n
= 6, CV 8%, and range 115-142 mg/dl), HDL-C 70±7 mg/dl (n = 6,
CV 10%, and range 64-84 mg/dl), and triglyceride 133±59 mg/dl (n
= 6, CV 45%, and range 82-227 mg/dl). His healthy mother was found
to be homozygous for the D442G mutation with mildly increased HDL-
C levels, 76 and 80 mg/dl, on two different occasions. His mother was
from southwest of Kanazawa. Other family members were healthy. In
kindred FHALP-1084, a female proband was found to be a D442G
homozygote. She and her family members were all healthy, except for
her sibling (a homozygote) with chronic hepatitis caused by hepatitis C
virus. The proband's father, an obligate heterozygote for the mutation,
died of cerebral vascular attack of unknown cause. This family was
from Kochi on the Shikoku Island.
DNA analysis
Single strand conformational polymorphism ofPCR products. Genomic
DNA was purified from white blood cells, and in vitro amplifications
of genomic DNA were performed by PCR (20, 22). Oligonucleotide
primers used for the amplification of exon 14 or 15 were based on
published sequences (15, 16). Single-strand conformational polymor-
phism (SSCP) analyses of the amplified DNA were performed as de-
scribed (24), with a slight modification (25). Briefly, 9 jil PCR products
were incubated with 1 ytl of alkaline solution (0.5 M sodium hydroxide,
10 mM EDTA) at 42°C for 5 min, heat-denatured at 96°C for 3 min,
and loaded on 10-20% native (non-SDS) gradient polyacrylamide gel
(Pagel; Atto Corp., Tokyo, Japan). The gels were run at 100 V for 10-
15 h at different conditions of 4°C and room temperature in 0.6 x TBE
buffer (1 x TBE buffer; 90 mM Tris-borate, pH 8.3, 4 mM EDTA).
Single-stranded conformers were visualized with a silver-staining kit
(Bio-Rad Laboratories, Richmond, CA). All PCR products were con-
firmed to be single bands resolved on agarose gel electrophoresis before
performing SSCP analyses. Direct sequencing of double-strand DNA
fragments of exon 14 and 15 were performed using internal sequencing
primers and T7 DNA polymerase (United State Biochemical Corp.,
Cleveland, OH) as described elsewhere (12).
Primer-mediated restriction map modification for the diagnosis of
point mutations. All mutagenic primers used for RFLP site-creating
PCR assays were based on published sequences (15, 16) with specific
nucleotide substitutions (oligonucleotide primer sequences for PCR, di-
rect sequencing, and primer-mediated restriction map modifications are
available from Dr. Inazu, if requested). Intl4 A transition was performed
with primer-mediated restriction map modifications of PCR products
using primers of 141A and 14IB29, and restriction enzyme NdeI (GIBCO
BRL Life Technologies, Inc., Gaithersburg, MD) as described elsewhere
(22). To confirm homozygosity for this mutation, a new RFLP site-
creating PCR assay using primers of 141A and 14IBGT, and restriction
enzyme RsaI was developed to recognize normal sequences (GTAN,
+ 1 to +4 position; N, any nucleotide) in the splice donor site of intron
14. PCR products of the normal allele at this site generate a 138-bp
fragment instead of 166-bp, after digestion of PCR products with 10 U
of RsaI (see Fig. 3). Methods to detect the two other point mutations
were developed similarly. For the exon 15 missense mutation (an A-
to-G transition: GAC/GGC), an Msp I site (5'-ccgg-3')-creating forward
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primer E1SA and intron 15 reverse primer 15IB were used. Digestions
of PCR products derived from the mutant allele with 10 U of Msp I,
gave rise to a 158-bp fragment instead of 179 bp resolved on 3.5%
NuSieve 3:1 agarose gel (FMC Corp. BioProducts, Rockland, ME) (see
Fig. 2). To confirm homozygosity of the D442G mutation, a Sall site
(5'-gtcgac-3')-creating PCR assay was also performed. SalI site-creating
forward primer E15AA and 15IB were used to detect the normal se-
quence (NTCGAC) corresponding to amino acid 442 (see Fig. 2). For
the detection of the intron 14 +3 position T insertion, the 141A foward
primer and an HpaI site(5'-gttaac-3') creating reverse primer 14IB3T
were used for the assay. The enzyme HpaI recognized the specific
sequence (GTTAAN) in PCR products derived from the T-inserted al-
lele, generating a 141-bp fragment instead of 166-bp (see Fig. 3).
Analytical measurements
Fasting plasma samples were isolated by clinical centrifuge within 30
min of venesection, and frozen at -80'C until used for the activity
assay. After measurements of CETP activity of plasma, the samples
were shipped to Columbia University in a dry-ice package. Plasma
CETP mass was determined by radioimmunoassay using l"I-labeled
mAb TP2 (20). TP2 binding to the variant CETP of D442G was normal,
because the epitope of TP2 is located between amino acids 463 and
475 (26).
3H-labeled CE containing HDL3 were prepared as described else-
where (19). In brief, sonicated lipids were prepared with 250 tCi (sp
act 74.0 Ci/mmol) of 3H-labeled cholesteryl linoleate (NEN Research
Products, Boston, MA), 4.66 jsmol fatty acid-free egg phosphatidylcho-
line (Sigma Chemical Co., St. Louis, MO), and 22 nmol butylated hy-
droxytoluene. The labeled lipids were incubated with the d > 1.125 g/
ml fraction of 50 ml fresh serum in the presence of a lecithin:cholesterol
acyltransferase inhibitor (1.4 mM dithionitrobenzoic acid) for 16 h at
37°C under nitrogen gas. Labeled HDL3 (d = 1.125-1.21 g/ml) was
isolated by ultracentrifugation at 10°C in a 50.3 Ti rotor (model L7-55;
Beckman Instruments, Inc., Fullerton, CA). CETP activity was measured
using 3H-labeled CE containing HDL3 as described elsewhere (27). In
brief, 40 Al of 10-fold diluted plasma was used as a source of CETP.
Unlabeled LDL (250 Ag cholesterol, d = 1.019-1.063 g/ml) and 20,000
dpm of 3H-labeled CE containing HDL3 (10-20 nmol of CE) were
incubated in the presence of 1.4 mM dithionitrobenzoic acid in 500 IL
of 50 mM Tris-HCl, 150 mM NaCl, 2 mM EDTA, pH 7.4 at 37°C for
3 h in a metabolic shaker. The reaction was stopped by chilling on ice
for 30 min. After the precipitation of LDL by the addition of a solution
containing heparin-manganese chloride and BSA fraction V (final con-
centration; 1.3 mg/dl, 92 mM and 4%, respectively), the radioactivity
in the HDL fraction was determined by liquid scintillation counting.
These conditions gave stable and linear transfer of labeled CE, represent-
ing less than 30% transfer of the initial radioactivity. CETP activity
measurements were performed in a triplicate assay and CETP specific
activity was expressed as nmol CE transferred X (lh)-' x (1 Ag
CETP)-1.
Blood samples were obtained after a 12-h overnight fast. Serum
cholesterol and triglyceride were determined enzymatically (TBA 20R;
Toshiba, Tokyo, Japan) (28, 29). The concentrations of apo A-I, A-Il, B,
C-II, C-Ill, and E were determined by immunoturbidimetry as described
(ApoAuto; Daiichi Chemical, Tokyo, Japan) (30). Intraassay and be-
tween assays CV for apolipoprotein measurements were less than 6%.
Serum HDL-C was determined by a heparin-calcium chloride precipita-
tion method (20). This method was validated by comparison of values
for HDL-C by the precipitation and preparative ultracentrifugation (d
= 1.063-1.21 g/ml) in samples of increased HDL-C levels caused by
hetero- or homozygous CETP deficiency (n = 22, HDL-C 47-230 mg/
dl). There was a good correlation (r = 0.986, P = 0.001) between the
two methods. However, there was a small difference (- 8 mg/dl; 95%
CI, 4-12 mg/dl) between two methods (values by the ultracentrifugation
minus the precipitation) in samples with HDL-C < 120 mg/dl, and a
4-11% underestimation of the values by the precipitation method in
samples with . 120 mg/dl. We have used only HDL-C values deter-
mined by the precipitation method in this report. LDL cholesterol was
calculated using the Friedewald formula (31).
Statistical analysis
All values were expressed as mean±SD. Multiple comparisons of lipo-
protein levels among genotypes were made by Fisher's least significant
difference only in variables whose P values were less than 0.05 by the
F-test in one-way ANOVA (32). 95% CI for allele or heterozygote
frequency were determined with F-distribution. For multiple regression
analysis on serum HDL-C, the nominal variable (i.e., CETP genotype)
was included as well as numerical variables (age, alcohol consumption,
cigarette smoking, and body mass index). Heterozygous CETP defi-
ciency was assigned a value of 1 for this variable, and normal CETP
genotype is assigned a value of 0. To bring distributions of measures
closer to normality, raw values of body mass index and triglyceride
were transformed by natural logarithm, and alcohol and cigarette con-
sumptions were by square root of values. Genetic variance of serum
HDL-C due to heterozygous CETP deficiency was determined as fol-
lows: [2pq(tis - i)2 + p2(IL2 - 1)2]/total phenotypic variance of serum
HDL-C; q, combined allele frequency for CETP deficiency; p, 1 - q;
,t, L, and ,2 are means of serum HDL-C levels in all subjects, subjects
with CETP deficiency, and subjects with non-CETP deficiency, respec-
tively (33).
Results
To identify CETP gene mutations, we screened subjects with
HDL-C - 100 mg/dl using SSCP analyses of PCR products.
All segments of 16 exons, and their flanking intronic sequences
and promoter regions (- 360 bp) were analyzed. Several variant
conformers were identified in the regions of exon 14 and 15.
These conformers were confirmed to have point mutations by
direct sequencing of the PCR products. One mutation was a
single-base A-to-G transition within exon 15 that changes the
codon for amino acid 442 of CETP, resulting in replacement
of the acidic residue aspartic acid (Asp) by the neutral residue
glycine (Gly) (D442G). Unrelated subjects with HDL-C 2 60
mg/dl (n = 312) and their family members were screened for
this mutation using an MspI site-creating PCR method (Fig. 2).
Remarkably, 4 homozygotes, 49 heterozygotes, and 4 genetic
compound heterozygotes with the D442G mutation were found.
A Sall site-creating PCR method was used to confirm homozy-
gosity of the mutation in subjects with the D442G mutation
(Fig. 2). Three pedigrees of subjects with CETP deficiency
involving the D442G mutation are shown (Fig. 1). Mildly to
moderately increased HDL tended to segregate with the D442G
mutation.
Another mutation was a novel intron 14 splice donor site
mutation. This mutation was a single-nucleotide insertion of T
at the +3 position of the intron 14 splice donor site (Intl4
T). In the kindred of FHALP-464, this novel splice donor site
mutation was identified in two generations as shown (Figs. 1
and 3). A daughter with no plasma CETP mass and activity, and
serum HDL-C 106 mg/dl, was found to be a genetic compound
heterozygote with two different splice donor site mutations in-
volving intron 14 (pedigree position 111-2). The null phenotype
in this subject indicates that the Intl4 T is a null allele, as
shown for the Intl4 A (20). Reduced CETP to - 59% of normal
levels in the two Intl4 T heterozygotes is also consistent with
the Intl4 T being a null allele. Serum HDL-C 127 mg/dl in the
proband appeared higher than expected for a single null allele
(20), suggesting involvement of other factors increasing HDL
level. All subjects with HDL-C 2 60 mg/dl were screened for
1874 Inazu et al.
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Figure 1. Pedigrees of CETP-deficient families caused by intron 14 splice donor site mutations and exon 15 missense mutation. The pedigree of
kindred FHALP-464 shows the concurrent segregations of two different splice donor site mutations involving intron 14. The daughter (III-2) was
a compound heterozygote with two different splice donor site mutations of Intl4 A and Intl4 T. Kindreds FHALP-277 and -1084 are families with
a homozygote for D442G mutation. FHALP-528 has a compound heterozygote (11-1) of D442G and Intl4 A mutations. Mildly to moderately
increased HDL cholesterol levels tended to segregate with the D442G mutation as shown in kindreds FHALP-277 and -1084. HDL-C levels in
D442G homozygotes were close or similar to those in heterozygotes in kindreds FHALP-277 and -1084. The proband (11-5) of kindred FHALP-
277 had vasospastic angina and xanthelasma. One obligate D442G heterozygote (I-1) in FHALP-1084 had history of cerebral vascular attack (CVA)
of unknown cause. Arrows (4-) indicate the proband of each family. Crosses represent deceased family members. N, normal CETP genotype; ND,
not determined. Plasma CETP (mg/liter), serum cholesterol (mg/dl), and HDL-C, (mg/dl) are shown in each member.
the Intl4 T using the PCR-based method (Fig. 3), but no others lipid, apolipoprotein, and CETP levels associated with the differ-
were found. ent CETP genotypes are shown. The table includes subjects iden-
The effects of the D442G and Intl4 T mutants on plasma tified either in initial screening of subjects with HDL-C 2 60
CETP and lipoprotein levels are summarized in Table I. The mg/dl or in subsequent family studies of the probands. Unaffected
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Figure 2. Rapid detection method for an exon 15 missense mutation (D442G) employing mutagenic primer-mediated restriction map modification.
Using a mutagenic primer E1SA and a reverse primer i5IB, gene amplification by PCR introduced an artificial MspI site in the PCR product only
for the A-to-G allele (D442G). Digestion of the PCR products with MspI generates polymorphic restriction fragments of lengths of 179 bp and/or
158 bp. The presence of the smaller fragment indicates the presense of the missense mutation. To confirm homozygosity or heterozygosity in the
region of interest, the other PCR-based assay was also carried out with a mutagenic primer E15AA and the 15IB primer which create a SalI site
in the PCR products for the normal allele at amino acid 442 N, normal; He, heterozygote; Ho, homozygote; M, the molecular size marker of OXx174/
HaeHI digestion.
family members were first-degree relatives of the probands (i.e.,
parents, children, or siblings). Subjects with the Intl4 A mutation
were similar to those described in a previous report (20). Homo-
zygotes for the D442G mutation had 57% lower plasma CETP
mass and 27% lower CETP specific activities compared to unaf-
fected family members. HDL-C levels in the homozygotes were
moderately increased (86±26 mg/dl) compared to unaffected
family members, but were not as high as in homozygotes with
the Intl4 A mutation (158±35 mg/dl, P < 0.001). Thus, the
D442G mutant allele was only partially defective. Compared to
unaffected family members, heterozygotes for the D442G muta-
tion had 34% lower plasma CETP levels (1.44±0.51 mg/liter)
and 55% lower specific activities (both P < 0.001). The differ-
ences in CETP specific activity comparing D442G heterozygotes
and homozygotes were not significant. The Int14 A heterozygotes
had similar reductions in plasma CETP concentration compared
to the D442G heterozygotes, but had normal CETP specific activ-
ity. In the D442G heterozygotes, decreased plasma CETP levels
and sp act led to a pronounced increase in HDL-C levels (91±23
mg/dl). The HDL-C levels in the D442G heterozygotes were
significantly higher than those in the Intl4 A heterozygotes
(69±15 mgldl, P < 0.001). Interestingly, the HDL-C levels in
the D442G heterozygotes were similar to those in the D442G
homozygotes. Thus, the phenotypic effects of the D442G muta-
tion on HDL are the same whether there are one or two mutant
alleles involved, and greater than expected for one partially defec-
tive allele, suggesting that the D442G allele is genetically domi-
nant. In compound heterozygotes with the genotype Intl4 A/
D442G, the mean HDL-C levels of 129 mg/dl were somewhat
lower than those in the homozygotes for the Intl4 A mutation,
but higher than in heterozygotes with the Intl4 A or D442G
mutation. These results are compatible with low but detectable
CETP activities in plasma of the compound heterozygote
(Intl4A/D442G).
The D442G homo- and heterozygotes showed increased apo
A-I levels compared to unaffected family members as shown
in Table II. Apo A-II levels were also increased in the D442G
heterozygotes. However, the elevation in apo A-I1 levels was
less remarkable so that the mass ratio of apo A-I/A-11 in the
D442G heterozygotes was increased as in homo- and heterozy-
gotes with the Intl4 A mutation. LDL cholesterol and apo B
levels were not changed in partial CETP deficiency caused by
the D442G homo- or heterozygotes, in contrast to decreased
LDL cholesterol and apo B found in subjects with complete
CETP deficiency (Tables I and II).
Frequencies of the two prevalent CETP gene mutations and
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Figure 3. Primer-mediated restriction map modification of PCR products used to screen for intron 14 splice donor site mutation due to T insertion
at position +3 in kindred FHALP-464. Using appropriate oligonucleotide primer sets, PCR-based assays were performed to detect normal sequence
of splice donor site, the Intl4 A, and the Intl4 T. 141A primer was located at 3' of intron 13; 14IBGT, 14IB29, and 14IB3T were mutagenic
primers at their 3' ends, and were located at 5' end of intron 14. The PCR product size was 166 bp. The pedigree positions are the same as those
in Fig. 1. PCR products for the proband (11-2) had artificially introduced HpaI site and one normal allele detected by RsaI PCR-RFLP, indicating
that he was Intl4 T heterozygote. The son (IHI-1) had one Intl4 A allele and one normal allele but no Intl4 T allele, indicating the Intl4 A
heterozygote. The daughter (II-2) also had both Intl4 T allele and Intl4 A allele but no normal allele, indicating a genetic compound heterozygote
with both Intl4 T and Intl4 A. The spouse of the proband (11-3) also had one Intl4 A allele, indicating the Intl4 A heterozygote. Therefore, the
Intl4 T and Intl4 A allele in the daughter (I1-2) were transmitted from the paternal and maternal side, respectively. Exonic and intronic sequences
are shown in capital and small letters, respectively. N denotes nucleotides in genomic DNA sequences which to C, T, and C nucleotide in amplified
DNA by RsaI, NdeI, and HpaI RFLP site-creating PCR assays, respectively. Mutant and/or normal DNA fragments are shown in each RFLP site-
creating PCR assay (denoted as M and N, respectively).
the distribution of HDL-C for each genotype are shown in Table
III. This table includes only unrelated subjects derived from the
screening study of subjects with HDL-C 2 60 mg/dl. Both the
Intl4 A and D442G mutations were extremely common in sub-
jects with HDL-C 2 60 mg/dl. The allele and heterozygote
frequencies for both mutations tended to increase with increas-
ing HDL-C up to 120 mg/dl. Above this level, the Intl4 A
mutation became more frequent, mainly due to the high preva-
lence of the homozygotes, and the D442G mutation was less
frequent. In the strata of HDL-C between 60 and 119 mg/dl,
the D442G mutation was two to four times more frequent than
the Intl4 A mutation, as reflected both in the overall mutant
allele and heterozygote frequency.
To estimate the prevalence of the Intl4 A or D442G muta-
tions in a sample of general population, blood specimens of
236 healthy Japanese men were screened. The mean values of
body mass index, serum cholesterol, TG, and HDL-C were
23.4+2.5 kg/m2 (mean+SD, range 13.2-36.0), 193±31 mg/dl
(range 116-269 mg/dl), 140±103 mg/dl (range 26-763 mg/dl),
49±13 mg/dl (range 24-95 mg/dl), respectively. The frequency
distribution of serum HDL-C values and the numbers of individ-
uals with heterozygous CETP deficiency are shown in Fig. 4.
Remarkably, 16 heterozygotes with the D442G mutation and 4
heterozygotes with the Intl4 A mutation were detected. All of
these heterozygotes had HDL-C values in the range 41-85 mg/
dl. The highest numbers of subjects with CETP gene mutations
were found in the group with HDL-C 60-69 mg/dl. The highest
relative frequency (56%) of heterozygous CETP deficiency was
observed for HDL-C values of 70-79 mg/dl. Heterozygote fre-
quencies with the Intl4 A and D442G mutations were 1.7%
(95% CI, 0.1-3.8%) and 6.8% (95% CI, 4.1-9.9%), respec-
tively. Thus, combined gene frequency for CETP mutant alleles
was q = 0.042. The mean HDL-C levels in subjects with hetero-
zygous CETP deficiency caused by either mutation (n = 20,
62±12 mg/dl) were significantly higher than those in subjects
without CETP deficiency (n = 216, 48+ 12 mg/dl, P = 0.0001).
The number of subjects with the Intl4 A mutation was too
small to permit meaningful comparisons of HDL-C levels for
the two different genotypes. Multiple regression analysis was
performed by stepwise forward selection, using five variables
(age, alcohol consumption, cigarette smoking, body mass index,
and CETP genotype). All factors, except for age, were signifi-
cant predictors of serum HDL-C levels in the sample of general
Japanese men (Table IV). The adjusted R2 values derived from
the four variables was 28%, and 18% after exclusion of the
CETP genotype from variables. Furthermore, 10% of total phe-
notypic variance of HDL-C was attributable to the presence of
genetic CETP deficiency in the sample of general Japanese men




Table I. Levels of Serum Lipid, CETP Mass and Specific Activity in D442G, Intron 14 T Insertion, and Intron 14 G(+1)-to-A Mutants
No. of
No. of subject
Mutations family (M/F) Age* Cholesterol*o TG*t LDL-C*s HDL-C*t CETP* Specific activity






















































* Age, lipid levels, CETP mass and sp act are mean ± SD, ranges, and the numbers analyzed. t To convert cholesterol and triglyceride values to
mmol/liter, multiply by 0.02586 and 0.01129, respectively. NS, not significant; NA, not applicapable.
in an analysis of the genetic variance based on gene frequencies
and genotypic means.
Discussion
Genetic deficiency of CETP due to the Intl4 A mutation is
well established as a common cause of increased HDL in the
Japanese. In the present study, two other CETP gene mutations
have been characterized. One of these is a missense mutation,
changing the codon of amino acid 442 from aspartate to glycine
(D442G). The other is a novel splice donor site mutation due
to a T insertion. Although there are distinctive differences in
its phenotypic expression, like the Intl4 A and Intl4 T, the
D442G mutant has potent effects on plasma HDL. The develop-
ment of PCR-based assays to detect these mutations allowed
population studies to be conducted. Remarkably, the D442G
mutation was found to be present in 18% of subjects with HDL-
C 2 60 mg/dl and in 7% of a random sample of Japanese men.
The D442G mutant thus appears to be about two to four times
more frequent than the common Intl4 A mutation. Although
these data are based on small selected samples, genetic CETP
deficiency is likely to be a major determinant of increased HDL-
C levels in the general Japanese population, with at least as
large an impact on HDL-C levels as well-known environmental
factors. The high prevalence of two common CETP gene muta-
tions suggests a biological advantage for CETP deficiency,
which could be related to several putative beneficial effects of
high HDL levels.
The D442G mutation was so frequently found, both in sub-
jects with increased HDL and in a general population sample,
that it could be questioned whether this was a neutral polymor-
phism that would not affect CETP function or HDL levels.






































































































































































































Table II. Apolipoprotein Levels in D442G, Intron 14 T Insertion, and Intron 14 G(+1)-to-A Mutants
A-I/A-Il




























































































































































































































































Apo levels are mean+SD, ranges and the numbers analyzed. NS, not significant.
However, in kindreds, the mutation tended to segregate with
high HDL-C levels (Fig. 1) and among subjects with increased
HDL-C, the frequency of the mutation tended to increase within
strata of increasing HDL-C levels (Table III). Also, subjects
with the mutation had higher HDL-C values than those without
the mutation in the general population sample (Fig. 4). Also, it
is mechanistically plausible that the D442G mutant should in-
crease HDL-C levels, since the mutant caused decreased plasma
CETP concentration and specific activity, with proportionate
effects on HDL-C (Table I). The D442G mutant is near a car-
boxy terminal region ofCETP shown to be essential for function
(14, 26). Finally, expression of the mutant cDNA in transfected
cells showed both impaired secretion and sp act of the mutant
CETP compared to the wild-type (23). Although the D442G
mutant potently increased HDL levels, the magnitude of the
effect was different in the different populations surveyed, possi-
bly reflecting selection bias and/or the lower levels of HDL-C
in an all-male population (Fig. 4). Initially, the D442G was
reported to cause a very high HDL-C level as a single mutant
allele (23). However, it is now evident that the D442G mutant
typically results in moderate increases in HDL-C (Table I,
Fig. 4).
Although the D442G allele was partially defective, several
aspects of its phenotypic expression suggest genetic dominance.
First, D442G heterozygotes and homozygotes had similar eleva-
tions in HDL-C. Second, the D442G heterozygotes had higher
HDL-C values than the Intl4 A heterozygotes (Table I). Thus,
one allele with the D442G mutation has a larger effect on HDL-
C than one null allele, even though the D442G mutant allele is
not completely defective. These results indicate that the partially
defective D442G allele tends to inhibit the expression of the
wild-type allele, and are consistent with the dominant negative
effects of the D442G cDNA in cell expression experiments
(23). Although the mechanism of genetic dominance is poorly
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Table 111. Frequencies of Two Prevalent CETP Gene Mutations in Unrelated Subjects with Increased HDL Cholesterol Levels
Frequency of Intl4A Frequency of D442G
Heterozygote Homozygote heterozygote and allele heterozygote and allele
HDL No. of Compound
cholesterol individuals Intl4A D442G Intl4A D442G heterozygote % (No./N, % (No./2N, % (No./N, % (No./2N,
group (M/F) (M/F) (M/F) (M/F) (M/F) (M/F) 95%CI) 95%CI) 95%CI) 95%CI)
mg/dl
60-79 100 (66/34) 4 (3/1) 13 (10/3) 0 0 0 4.0 (2.2-8.7) 2.0 (1.6-4.5) 13.0 (8.0-19.2) 6.5 (3.9-10.0)
80-99 82 (33/49) 3 (2/1) 12 (5/7) 1 (1/0) 1 (0/1) 0 3.7 (3.1-8.9) 3.0 (2.5-6.2) 14.6 (10.2-24.5) 8.5 (6.0-17.9)
100-119 79 (26/53) 6 (2/4) 18 (7/11) 0 2 (0/2) *3 (0/3) 7.6 (6.6-16.8) 5.7 (4.9-9.5) 22.8 (15.2-30.4) 15.2 (10.9-20.1)
120- 51 (30/21) 6 (2/4) 6 (4/2) 14 (10/4) 0 12 (0/2) 11.8 (10.9-22.1) 35.3 (28.3-42.2) 11.8 (10.9-22.1) 7.8 (4.0-13.4)
Total 312 (155/157) 19 (9/10) 49 (26/23) 15 (11/4) 3 (0/3) 5 (0/5) 6.1 (5.4-8.7) 8.7 (6.9-10.7) 15.7 (12.5-19.2) 9.5 (7.7-11.5)
* The genotypes are two subjects with Intl4 A/D442G and one with Intl4 A/Intl4 T. I The genotypes are two subjects with Intl4 A/D442G. 2N
indicates the number of chromosomes analyzed. CI, confidence interval.
understood, it could reflect formation of multimeric species of
CETP during cellular secretion and/or involvement of multimers
in the lipid transfer process.
A novel intron 14 splice donor site mutation caused by a T
insertion at the +3 position relative to the exon 14/intron 14
boundary (Intl4 T) was also identified in this study. Plasma
CETP mass and activity were undetectable in a subject who
was a genetic compound heterozygote with both Intl4 T and
Intl4 A mutations involving the same intron 14 splice donor.
Therefore, the +3 position T insertion yields a null allele with
no CETP produced (Fig. 1 kindred FHALP-464). In addition
to the invariant GT dinucleotide located in the first two positions
of a splice donor site, mutations at the +3 position also have
been shown to cause defective alleles in several genetic disor-
ders (34). Abnormal splicing in both mutants involving intron
14 is likely to result in a premature translation termination at
the fourth codon encoded by exon 15. This would occur either
with exon 14 skipping or with activation of a predicted cryptic
splice donor site located 10 nt upstream from the exon 14/intron
14 junction.
The Intl4 A mutation was initially found to be common
among selected families with markedly increased HDL-C (20).
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Figure 4. Frequencies of heterozygous CETP deficiency caused by two
prevalent mutations in general Japanese men from Kanazawa district.
The frequency of heterozygous CETP deficiency due to either the Intl4
A or D442G mutation was determined by PCR-based methods. In 236
healthy Japanese men, 4 Intl4 A heterozygotes and 16 D442G heterozy-
gotes were identified. The heterozygote with either mutant were found
in the range 41-85 mg/dl.
More systematic studies revealed that this mutant was frequent
in subjects with mildly to moderately increased HDL-C levels,
and in as many as 1-2% of the general Japanese population
(22). These results are comparable to those in the present study
(Table III, Fig. 4). Although the Intl4 A mutation is a common
cause of hyperalphalipoproteinemia (20, 22), considered alone
this mutation would not be sufficiently prevalent to influence the
distribution of HDL-C levels in the general Japanese population.
Unexpectedly, the frequency of the D442G mutation was found
to be considerably higher than that of the Intl4 A mutation
(Table III, Fig. 4). Thus, the present study has established for
the first time that genetic CETP deficiency, mainly due to the
D442G mutant and to a lesser extent to the Intl4 A mutant, is
sufficiently common to influence HDL-C levels in the general
Japanese population. The high prevalence of two different
CETP mutations could suggest a biological advantage of CETP
deficiency, related to putative beneficial effects of increased
HDL levels.
HDL may have several different beneficial biological activi-
ties. As an antiatherogenic agent, HDL or its major protein
(i.e., apo A-I) may facilitate cholesterol efflux from cells in
atherosclerotic plaque (3, 4). HDL also promotes prostacyclin
secretion and stabilization (35) and acts as a major carrier of
lipid hydroperoxides, leading to less retention of oxidized lipids
in LDL, consequently reducing its atherogenic potential (36).
Table IV. Multiple Regression Coefficients, F-values, and
Adjusted R2 for Serum HDL Cholesterol in a General Sample
of Japanese Men
Adjusted R2
Step variable Coefficient SE F-value Total Increment
1 CETP genotype* 0.281 0.050 31.5 0.094 0.094
2 Body mass index -0.737 0.126 34.1 0.195 0.101
3 Cigarette smoking -0.024 0.006 18.9 0.253 0.058
4 Alcohol consumption 0.033 0.011 8.7 0.277 0.024
* Heterozygous CETP deficiency and normal CETP genotype are as-
signed a value of 1 and 0, respectively. Intercept for multiple regression
is 6.143. HDL cholesterol and body mass index are transformed to ln(x)
of variables. Amounts of cigarettes and alcohol (units) are transformed
to square root of variables. n = 236.
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In addition, high HDL levels may protect against gram-negative
bacteremia through the inactivation of bacterial lipopolysaccha-
ride (37). Therefore, high HDL could provide a biological ad-
vantage in atherosclerotic or infectious diseases. Indeed, some
epidemiological studies suggest that high HDL is associated
with decreased total mortality from all causes, not just CHD
(38, 39). The homozygous state of CETP deficiency does not
produce obvious deleterious effects on health or reproduction.
The high prevalence of the heterozygous CETP deficiency could
be related to some biological advantage in CETP deficiency
state or random genetic drift of defective alleles or both. How-
ever, there is currently no direct evidence of any biological
advantage for CETP deficiency.
HDL consist of a heterogenous population of particles with
varied apolipoprotein compositions; e.g., HDL with apo A-I
only (Lp A-I), HDL with both apo A-I and A-II (LpA-I:A-
II). Recent studies in transgenic mice suggest that Lp A-I are
antiatherogenic; Lp A-I:A-ll, on the other hand, may suppress
the antiatherogenic property of Lp A-I or even be actively pro-
atherogenic (40, 41). However, such specific effects of HDL
subpopulations have not been seen in epidemiological studies
(42). In complete CETP deficiency, apo A-I and A-fl were both
increased, with a remarkable increase in the apo A-I: A-II ratio,
perhaps indicating that antiatherogenic potential of HDL is
stronger in CETP deficiency. In addition, 1 Intl4 A homozygote
(20), 3 Intl4 A heterozygotes, and 4 D442G heterozygotes had
evidence or history of cerebro vascular disease, and 2 Intl4 A
heterozygotes and 5 D442G heterozygotes had evidence or his-
tory of CHD including vasospastic angina in 22 Intl4 A homo-
zygotes, 4 D442G homozygotes, S compound heterozygotes,
57 Intl4 A heterozygotes, 2 Intl4 T heterozygotes, and 93
D442G heterozygotes including obligate heterozygotes. How-
ever, there is no evidence for atherosclerotic CHD in any cases
of complete CETP deficiency. Taking high prevalences of het-
erozygous CETP deficiency in the general population into ac-
count, the prevalences of cardio- or cerebro-vascular diseases
in CETP deficiency are not necessarily high. Taken together
with recent studies of CETP transgenic mice (43), CETP could
be an intrinsic proatherogenic protein under conditions of diets
rich in cholesterol and saturated fat. However, CETP is involved
in reverse cholesterol transport, which may have antiatherogenic
effects as long as CE acceptor lipoproteins (i.e., chylomicron
and VLDL remnants) are efficiently removed from the circula-
tion (14). Although lower CETP levels in plasma could reduce
atherogenic potential through decreasing CE contents in VLDL
or chylomicron remnants as well as increasing HDL, it is not
established whether decreased CETP levels are antiatherogenic
in human. Population studies with a larger number of individu-
als are required to compare prevalences of CHD, cerebrovascu-
lar disease, and other causes of morbidity and mortality in fami-
lies with CETP deficiency with those in a control population.
The distribution of HDL-C levels in other ethnic groups (44)
are similar to those in the Japanese (22), consistently showing
skewness towards higher levels (Fig. 4). Furthermore, subjects
with very high HDL-C levels are not rare in the Japanese (22)
and other ethnic groups (45). However, genetic factors de-
termining HDL-C levels in the general population have been
poorly understood (6-11). In addition to genetic CETP defi-
ciency, an apo C-Ill variant (46), hepatic lipase deficiency (47),
a putative plasma CETP inhibitor (48), and increased apo A-I
production rate (13) are candidate genetic causes of increased
HDL-C levels. However, except for genetic CETP deficiency,
the prevalence of these defects is unknown. It has been sug-
gested that rare recessive genes probably do not explain a sig-
nificant fraction of the phenotypic variation in HDL levels in
the population (6, 7). Genetic CETP deficiency in other ethnic
groups has not been documented. However, it is likely that
more CETP mutants will be discovered in subjects with in-
creased HDL both in the Japanese and other populations, be-
cause a variety of different molecular defects causing CETP
deficiency have been reported; e.g., splicing defects, missense
mutation, and nonsense mutation (12, 23, 49). It is interesting
to note that the independent, strong, inverse relation between
HDL-C levels and incidence ofCHD was initially established in
men of Japanese descent living in Hawaii (50) and subsequently
confirmed in most other ethnic groups (1). The incidence of
CHD death in Japan is relatively low compared with those in
other countries (51). Since the frequency of heterozygous CETP
deficiency is shown to be as high as 9% in Japan, CETP defi-
ciency could have a considerable impact on HDL-C levels in
the population. It is likely that CETP deficiency is a major
genetic cause of high HDL-C levels in the general Japanese
population. Furthermore, it is possible that genetic CETP defi-
ciency itself represents a negative CHD risk factor, contributing
to a relatively low incidence of CHD in Japan.
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